Financial analysis of cardiovascular wellness program provided to self-insured company from pharmaceutical care provider's perspective

Journal of the American Pharmacists Association

Volumn 45, Issue 5, 2005, Pages 588-592

  Wilson, Justin B ^a,b,f   Osterhaus, Matt C ^c,d   Farris, Karen B ^d   Doucette, William R ^d   Currie, Jay D ^d   Bullock, Tammy ^c,d   Kumbera, Patty ^d,e  

^a Valu Med Pharmacy   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c Osterhaus Pharmacy   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e Outcomes Pharmaceutical Health Care   (United States)

^f NONE   (United States)

Author keywords

Community and ambulatory pharmacy; Disease management; Pharmacoeconomics; Pharmacy management; Wellness

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH INSURANCE; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; PHARMACEUTICAL CARE; PHARMACIST; PHARMACY; WELLBEING; COST; DIABETES MELLITUS; ECONOMICS; HEALTH CARE PERSONNEL; HEALTH PROMOTION; ORGANIZATION AND MANAGEMENT;

CARDIOVASCULAR DISEASES; COSTS AND COST ANALYSIS; DIABETES MELLITUS; HEALTH PERSONNEL; HEALTH PROMOTION; INSURANCE, HEALTH; PHARMACEUTICAL SERVICES;

EID: 33644644272     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/1544345055001346     Document Type: Article

References (8)

1. American Heart Association. Heart disease and stroke statistics-2003 Update. Dallas: American Heart Association; 2002.
2. Grover SA, Ho V, Lavoie F, et al. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives with statins? Arch Intern Med. 2003;163:333-9.
3. Lamy A, Yusuf S, Pogue J, et al. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation study. Circulation. 2003;107:960-5.
4. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of community pharmacy diabetes care program. J Am Pharm Assoc. 2003;43:173-84.
5. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in Project ImPACT: Hyperlipidemia. J Am Pharm Assoc. 2000;40:143-4.
6. Garrett DG, Bluml BM. Patient Self-Management Program for Diabetes: first-year clinical, humanistic, and economic outcomes. J Am Pharm Assoc. 2005;45:130-7.
7. Norwood GJ, Sleath B, Caiola SM, et al. Costs of implementing pharmaceutical care in pharmacies. J Am Pharm Assoc. 1998;38:755-61.
8. National Cholesterol Education Program. Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Bethesda, Md.: National Heart, Lung, and Blood Institute, National Institutes of Health; 2001. Publication 01-3670.